Get the Stockscreener App
0.3457
0.95%
-0.0033
Citius Pharmaceuticals Inc stock is traded at $0.3457, with a volume of 207.65K.
It is down -0.95% in the last 24 hours and down -20.35% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
See More
Previous Close:
$0.349
Open:
$0.345
24h Volume:
207.65K
Relative Volume:
0.17
Market Cap:
$63.07M
Revenue:
-
Net Income/Loss:
$-32.54M
P/E Ratio:
-1.7285
EPS:
-0.2
Net Cash Flow:
$-29.06M
1W Performance:
-11.45%
1M Performance:
-20.35%
6M Performance:
-50.96%
1Y Performance:
-55.46%
1-Day Range:
$0.3413
$0.3599
1-Week Range:
$0.3413
$0.42
52-Week Range:
$0.33
$1.07
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India
CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com
Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Closing Bell Recap: Citius Pharmaceuticals Inc (CTXR) Ends at 0.37, Reflecting a -8.22 Downturn - The Dwinnex
There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.39 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.39 - Investing.com
Analyzing the Impact of Earnings Reports on Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance - The InvestChronicle
Is Citius Pharmaceuticals Inc (CTXR) a threat to investors? - US Post News
Market Resilience: Citius Pharmaceuticals Inc (CTXR) Finishes Weak at 0.43, Down -2.60 - The Dwinnex
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Market Fluctuations - The InvestChronicle
Point72 DIFC Ltd Makes New $29,000 Investment in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals Inc (CTXR) can make a big difference with a little luck - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Post-Trade Analysis: Citius Pharmaceuticals Inc (CTXR) Climbs 0.95, Closing at 0.52 - The Dwinnex
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short Interest - MarketBeat
Citius Pharmaceuticals Inc’s results are impressive - US Post News
Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com South Africa
Citius Pharmaceuticals extends executive and warrant agreements - Investing.com
Armistice Capital LLC Purchases New Position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - MarketBeat
Financial Snapshot: Analyzing Citius Pharmaceuticals Inc (CTXR)’s Key Ratio Metrics - The Dwinnex
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
Cettire shares skyrocket - ShareCafe
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc (CTXR)’s Day in Review: Closing at 0.50, Down by -2.90 - The Dwinnex
The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News
Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News
Citius Pharmaceuticals defers FDA milestone payment - Investing.com
Citius Pharmaceuticals defers FDA milestone payment By Investing.com - Investing.com UK
Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Financial Metrics Check: Citius Pharmaceuticals Inc (CTXR)’s Ratios for Trailing Twelve Months - The Dwinnex
Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
Citius Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com Australia
Insider’s View: Deciphering Citius Pharmaceuticals Inc (CTXR)’s Financial Health Through Ratios - The Dwinnex
Can you still get a good price for Citius Pharmaceuticals Inc (CTXR) Shares at this point? - US Post News
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - The Malaysian Reserve
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Malaysian Reserve
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):